Veterinary clinical pathology · 2025
Comparison of Hemostatic Activity in Canine Leukoreduced Cryoprecipitate, Cryopoor Plasma, and Fresh Plasma.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perego Roberta, Spada Eva, Baggiani Luciana, Ravasio Giuliano, Zucca Enrica, Vanosi Graziella, Ruffo Giancarlo, Proverbio Daniela
Аннотация
BACKGROUND: To date, no studies have reported the evaluation of hemostatic activity in canine leukoreduced cryoprecipitate (LR-CRYO) and leukoreduced cryopoor plasma (LR-CPP).
OBJECTIVES: We aimed to compare the hemostatic activity of LR-CRYO and LR-CPP to leukoreduced fresh plasma (LR-FP) and to evaluate the preservation of LR-CRYO by refrigeration and refreezing after thawing.
METHODS: Four hundred fifty milliliters of fresh blood was collected from ten donor dogs, leukoreduced, and separated into LR-FP, then frozen (-20°C) to obtain leukoreduced fresh frozen plasma (LR-FFP). LR-FFP was further separated into LR-CRYO and LR-CPP. LR-CRYO was frozen, thawed, and divided into two bags, one refrigerated for 24 h and one refrozen for 7 days. Factor VIII (FVIII) and X (FX) activity, prothrombin time, activated partial thromboplastin time, antithrombin III (ATIII) activity (ATA), total protein, albumin, fibrinogen, and D-dimer concentration, and von Willebrand Factor (vWF) activity were measured in LR-FP, LR-CRYO, LR-CPP, refrigerated, and refrozen LR-CRYO.
RESULTS: FVIII activity was higher in LR-CRYO (p = 0.0001) versus LR-FP. vWF activity (p < 0.0001) and fibrinogen concentration (p = 0.0012) were lower in LR-CPP versus LR-FP. FX activity was higher in LR-CPP (p < 0.0001) and LR-FP (p = 0.0002) versus LR-CRYO, and albumin concentration was higher in LR-CPP versus LR-FP (p < 0.0001) and LR-CRYO (p < 0.0001). No statistically significant difference was found in refrigerated or refrozen LR-CRYO as compared with LR-CRYO, excluding ATA, which was lower (p = 0.0062) in refrigerated LR-CRYO.
CONCLUSIONS: Because the concentration of FVIII is higher in LR-CRYO than in LR-FP, LR-CRYO is a possible component therapy when this factor is deficient. Since no statistically significant difference was found in refrozen LR-CRYO as compared with LR-CRYO, LR-CRYO can be frozen after thawing for reuse.
OBJECTIVES: We aimed to compare the hemostatic activity of LR-CRYO and LR-CPP to leukoreduced fresh plasma (LR-FP) and to evaluate the preservation of LR-CRYO by refrigeration and refreezing after thawing.
METHODS: Four hundred fifty milliliters of fresh blood was collected from ten donor dogs, leukoreduced, and separated into LR-FP, then frozen (-20°C) to obtain leukoreduced fresh frozen plasma (LR-FFP). LR-FFP was further separated into LR-CRYO and LR-CPP. LR-CRYO was frozen, thawed, and divided into two bags, one refrigerated for 24 h and one refrozen for 7 days. Factor VIII (FVIII) and X (FX) activity, prothrombin time, activated partial thromboplastin time, antithrombin III (ATIII) activity (ATA), total protein, albumin, fibrinogen, and D-dimer concentration, and von Willebrand Factor (vWF) activity were measured in LR-FP, LR-CRYO, LR-CPP, refrigerated, and refrozen LR-CRYO.
RESULTS: FVIII activity was higher in LR-CRYO (p = 0.0001) versus LR-FP. vWF activity (p < 0.0001) and fibrinogen concentration (p = 0.0012) were lower in LR-CPP versus LR-FP. FX activity was higher in LR-CPP (p < 0.0001) and LR-FP (p = 0.0002) versus LR-CRYO, and albumin concentration was higher in LR-CPP versus LR-FP (p < 0.0001) and LR-CRYO (p < 0.0001). No statistically significant difference was found in refrigerated or refrozen LR-CRYO as compared with LR-CRYO, excluding ATA, which was lower (p = 0.0062) in refrigerated LR-CRYO.
CONCLUSIONS: Because the concentration of FVIII is higher in LR-CRYO than in LR-FP, LR-CRYO is a possible component therapy when this factor is deficient. Since no statistically significant difference was found in refrozen LR-CRYO as compared with LR-CRYO, LR-CRYO can be frozen after thawing for reuse.